Business Context and Reporting Period
Company: Bio-Rad Laboratories, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Bio-Rad operates in two primary segments: Life Science (reagents, instruments, software for research) and Clinical Diagnostics (tests for disease detection). The company divested its analytical instruments product lines in 2000-2001 to focus on these core segments. It maintains distribution channels in 30 countries and employs approximately 4,600 full-time employees globally.
Key Financial Metrics
Note: Specific revenue, profit, cash flow, and debt totals for the fiscal year are incorporated by reference in Exhibit 13.1 and are not explicitly stated in the provided text. The following metrics are available from the filing text:
- Research & Development (R&D) Expenses: $82.9 million for 2002 (compared to $76.5 million in 2001 and $68.1 million in 2000).
- Stock Performance (Class A): High of $51.00 and Low of $27.45 during 2002.
- Stock Performance (Class B): High of $50.25 and Low of $27.50 during 2002.
- Market Value (March 4, 2003): Approximately $596.6 million for Class A and $20.7 million for Class B held by non-affiliates.
- Reserve for Doubtful Accounts: Ended 2002 at $12.122 million.
- Valuation Allowance for Deferred Tax Assets: Ended 2002 at $12.867 million.
Material Changes and Operational Highlights
- Strategic Focus: Completed divestiture of analytical instruments product lines to concentrate on Life Science and Clinical Diagnostics.
- Acquisition History: Acquired Pasteur Sanofi Diagnostics (PSD) in 1999 for $210 million, expanding reach in HIV/infectious disease diagnostics and international markets (Latin America, Africa, France).
- Customer Concentration: No single customer accounted for more than 2% of total net sales in 2002.
- Seasonality: Operations are not inherently seasonal, though European summer vacations typically negatively impact third-quarter sales and operating income.
- Accounting Firm Change: Filed a Form 8-K on July 10, 2002, noting a change in independent public accountants. The 2002 audit was performed by Deloitte & Touche LLP; prior years were audited by Arthur Andersen LLP (who have ceased operations).
Outlook, Risks, and Management Commentary
- Government Funding Risk: A significant portion of Life Science customers depend on government grants. A reduction in funding would detrimentally affect this segment.
- BSE Testing Dependency: Bio-Rad is the leading global provider of Bovine Spongiform Encephalopathy (mad cow) tests. Revenue is heavily influenced by government mandates. Risks include changes in test standards, technology, or government demand.
- Regulatory Environment: Products are subject to FDA regulations (pre-marketing approval, good manufacturing practices) and international environmental laws regarding hazardous waste and emissions.
- Competition: Markets are competitive with no single dominant player. Competitors include Amersham Biosciences, Invitrogen, Abbott Laboratories, and Roche Diagnostics.
- Dividend Policy: The company has never paid cash dividends and has no present plans to do so.
Investor Verification Checklist
- Verify the specific Net Sales, Net Income, and Cash Flow figures in Exhibit 13.1 (Annual Report to Stockholders), as these are not detailed in the 10-K text provided.
- Review the "Management's Discussion and Analysis" in Exhibit 13.1 for detailed segment performance and margin analysis.
- Confirm the status of the executive management transition plans announced via Form 8-K on December 23, 2002.
- Assess the impact of the change in auditors from Arthur Andersen to Deloitte & Touche on financial reporting consistency.
- Monitor government funding trends for research grants and regulatory mandates for BSE testing, as these are material revenue drivers.